Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Okayama University research: Therapeutic potential of stem cells for treating neurodegenerative disease


News provided by

Okayama University

16 Feb, 2021, 09:27 GMT

Share this article

Share toX

Share this article

Share toX

OKAYAMA, Japan, Feb. 16, 2021 /PRNewswire/ --  Researchers at Okayama University report in Scientific Reports that a particular type of stem cell has therapeutic benefits for patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease that affects bodily motion and for which there is no cure yet.

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease resulting in the gradual loss of motor nerve cells (neurons) that control certain muscles, ultimately leading to fatal paralysis. As there is no cure for the disease, therapeutic strategies are highly needed. Now, Professor ABE Koji and Associate Professor YAMASHITA Toru from Okayama University and colleagues have investigated the potential of a particular kind of stem cells ('Muse cells'), which can recognize damaged sites in the human body, for treating ALS. Experiments in mice reveal promising potential therapeutic benefits for ALS patients.

Muse cells are a kind of stem cell occurring in the bone marrow, blood and connective tissues in the human body. They can identify damaged tissue, and when injected, they can locate a damaged site — this is possible because Muse cells produce molecules that recognize substances created in damaged or apoptotic (dying) cells. Muse cells can not only locate the damage but also contribute to tissue repair, by transforming (differentiating) into healthy replacement cells. Inspired by this property, Abe and colleagues studied whether there is therapeutic potential in releasing Muse cells in ALS patients.

First, the researchers determined the best route for administering Muse cells. They compared the results for intravenous (into veins) and intrathecal (into the spinal canal) injections in mice. Intravenous injection gave the best results, with Muse cells appearing in different relevant body areas.

The scientists subsequently looked at the effect of intravenous administration of Muse cells into ALS mice. They established that the cells migrated to the spinal cord (a key part of the central nervous system). The Muse cells did not differentiate into neurons, but mainly into so-called astroglial cells. There are beneficial aspects associated with the latter, including stimulating the growth of nervous tissue and modulating inflammatory responses. The researchers' findings also suggested that the injection of Muse cells prevented the shrinking of muscle cells (amyotrophy) in ALS mice.

The study of Abe and colleagues represents a valuable result in the context of establishing a potential strategy for treating ALS. In the words of the scientists: "[Our] study successfully achieved … the systematic administration of Muse cells that showed a significant clinical benefit for the ALS mice model" and "Muse cells can be a promising cell resource for the treatment of ALS patients."

Background

Amyotrophic lateral sclerosis: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the part of the nervous system that governs bodily motion. It is characterized by a progressive loss of nerve cells controlling voluntary muscles. Symptoms at the early stage of ALS include stiff muscles, weakness in a limb and slurred speech. Due to the continued loss of motor neurons, control of the muscles needed for moving, speaking, eating and breathing is eventually lost, leading to paralysis and respiratory failure. There is no cure for this fatal disease. Existing treatments are aimed at improving the symptoms. Now, Professor ABE Koji and Associate professor YAMASHITA Toru from Okayama University and colleagues have started to investigate the therapeutic potential of Muse cells, which can recognize and cure damaged sites in the human body, for treating ALS. Experiments in mice have shown promising results.

Multi-lineage differentiating stress enduring cells: Multi-lineage differentiating stress enduring cells ('Muse cells') are a kind of pluripotent stem cell — that is, a cell that can differentiate into several 'standard' cell types encountered in the human body. They occur in the connective tissues of organs, bone marrow and blood. Muse cells were discovered in 2010 by the research group of Dr.Mari Dezawa. Muse cells can repair tissue in vivo, a property that has been investigated in mouse models with pathologies including muscle degeneration, stroke and spinal cord injury. Now, Abe and colleagues have performed a study addressing the potential of Muse cells for identifying and repairing damaged neurons in the context of ALS.

Reference

Toru Yamashita, Yoshihiro Kushida, Shohei Wakao, Koh Tadokoro, Emi Nomura, Yoshio Omote, Mami Takemoto, Nozomi Hishikawa, Yasuyuki Ohta, Mari Dezawa and Koji Abe. Therapeutic benefit of Muse cells in a mouse model of amyotrophic lateral sclerosis, Scientific Reports 10, 17102 (2020).DOI : 10.1038/s41598-020-74216-4 https://www.nature.com/articles/s41598-020-74216-4

Link to related Fig.1
https://www.okayama-u.ac.jp/up_load_files/research_highlights/127_image_1.jpg

Caption: Muse cells administered by tail vein injection reached the lumbar spinal cord and differentiated mainly into astrocytes.

Reference (Okayama Univ. e-Bulletin): Professor ABE's team

OU-MRU Vol.74:Rising from the ashes—dead brain cells can be regenerated after traumatic injury

OU-MRU Vol.79:Novel blood-based markers to detect Alzheimer's disease

Correspondence to

Professor ABE Koji, M.D., Ph.D.
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558,
Japan
E-mail: abekabek(a)cc.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.

https://www.okayama-u.ac.jp/user/med/shinkeinaika/english.html

Further information

Okayama University
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Public Relations Division
E-mail: www-adm(a) adm.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.
Website: //www.okayama-u.ac.jp/index_e.html 
Okayama Univ. e-Bulletin: //www.okayama-u.ac.jp/user/kouhou/ebulletin/

Okayama University Medical Research Updates (OU-MRU)

The whole volume : OU-MRU (1- )

Vol.1:Innovative non-invasive 'liquid biopsy' method to capture circulating tumor cells from blood samples for genetic testing

Vol.86:Plates and belts — a toolkit to prevent accidental falls during invasive vascular proceduresa 

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.